Le Lézard
Classified in: Health
Subject: OFR

RADNET ANNOUNCES PROPOSED $175 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK


LOS ANGELES, June 13, 2023 /PRNewswire/ -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced today that it intends to offer and sell, subject to market and other conditions, an underwritten public offering of $175,000,000 of shares of common stock. In addition, RadNet intends to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 shares of common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

RadNet intends to use the net proceeds from the proposed offering to pay down $100 million of its first lien term loans and for working capital and general corporate purposes.

Jefferies and Raymond James are acting as joint bookrunning managers for the offering.

The securities described above are being offered by RadNet pursuant to a shelf registration statement previously filed and declared effective by the Securities and Exchange Commission ("SEC"). A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; or from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863, or by email at [email protected]. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About RadNet, Inc.

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.  RadNet has a network of 363 owned and/or operated outpatient imaging centers.  RadNet's markets include California, Maryland, Delaware, New Jersey, New York, Florida and Arizona.  In addition, RadNet provides radiology information technology and artificial intelligence solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of over 9,000 employees.

Forward-Looking Statements

RadNet cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements relating to the offering, including the timing and size of the offering and the anticipated use of proceeds therefrom and the grant of the option to purchase additional shares. The inclusion of forward-looking statements should not be regarded as a representation by RadNet that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in RadNet's business, including, without limitation: the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed public offering and the other risks and uncertainties described in the Company's filings with the SEC, included under the heading "Risk Factors" in the Company's Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and RadNet undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE RadNet


These press releases may also interest you

at 11:25
KCAS Bio continues to deliver against both growth objectives and more integrated customer service offerings. KCAS Bio has partnered with Crux Biolabs, a leading provider of flow cytometry and bioanalytical services located in Melbourne, Australia....

at 11:15
Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study...

at 11:13
Sporting Life, the iconic sports and style retailer, is hosting the 24th annual Sporting Life 10K, sending thousands of participants down Yonge Street, with net proceeds supporting Campfire Circle. Since 2000, the Sporting Life 10K has raised more...

at 11:00
PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") , a biotechnology company focused on the research, development, and manufacturing of LaNeotm MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has...

at 11:00
MyAdvisor, a holistic wellness company, is pleased to announce the opening of a new office in Bedford, Pennsylvania. This strategic expansion is driven by the company's sustained growth and commitment...

at 11:00
Mozart Therapeutics, the leading developer of CD8 Treg network modulators, today announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells. The data will be presented...



News published on and distributed by: